Vaxcyte to Present at Upcoming Investor Conferences

FOSTER CITY, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that Company management will participate in and host one-on-one meetings at the following virtual investor conferences:

Jefferies London Healthcare Conference
November 16 – 19, 2021

• Fireside Chat available on-demand starting Thursday, November 18 at 3:00am ET.
  

Piper Sandler 33rd Annual Virtual Healthcare Conference
November 29 – December 2, 2021

• Fireside Chat available on-demand starting Monday, November 22 at 10:00am ET.
  

Evercore ISI 4th Annual HealthCONx Virtual Conference
November 30 – December 2, 2021

• Fireside Chat will take place live on Wednesday, December 1 at 4:45pm ET.
  

The webcast of these presentations can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com. A replay of each webcast will be available for approximately 30 days following the conference.

About Vaxcyte
Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCF^TM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. Vaxcyte’s lead vaccine candidate, VAX-24, is a preclinical, 24-valent broad-spectrum pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease. Vaxcyte’s pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of at least 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease by targeting the keystone pathogen responsible for this chronic, oral inflammatory disease. For more information, visit www.vaxcyte.com.

Contacts:
Andrew Guggenhime, President and Chief Financial Officer
Vaxcyte, Inc.
650-837-0111
investors@vaxcyte.com

Janet Graesser, Vice President, Corporate Communications and Investor Relations
Vaxcyte, Inc.
917-685-8799
media@vaxcyte.com